Results 31 to 40 of about 16,624 (211)

Development and Validation of HPLC-UV Method for the Determination of Favipiravir in Human Plasma

Разработка и регистрация лекарственных средств, 2022
Introduction. Coronavirus disease (COVID-19) is an acute infectious disease caused by SARS-CoV-2 (severe acute respiratory syndrome-related coronavirus 2).
T. N. Komarov, P. K. Karnakova, O. A. Archakova, D. S. Shchelgacheva, N. S. Bagaeva, I. E. Shohin, K. Ya. Zaslavskaya, P. A. Bely   +7 more
doaj   +1 more source

Conventional and synchronous spectrofluorometric determination of the recently administered drugs for treatment of COVID-19 favipiravir and apixaban

Scientific Reports, 2022
COVID-19 is a fast-spreading pandemic that is caused by SARS-CoV-2 viral pathogen. Combination therapy of the antiviral favipiravir and the anticoagulant apixaban is one of the efficient treatment regimens.
Heba Samir Elama, Abdallah M. Zeid, Shereen M. Shalan, Yasser El-Shabrawy, Manal I. Eid   +4 more
doaj   +1 more source

Follow-up of Favipiravir-Induced Nail Fluorescence: Implications for Nail and Drugs

Dermatology Practical & Conceptual, 2023
Introduction: Favipiravir creates fluorescence on nails, which can be seen with Wood's light. Objectives: The objectives of this study are to examine the properties of fluorescence in the nail due to favipiravir and to observe whether other drugs also
Hüsna Güder, Zeynep Güneş Özünal
doaj   +1 more source

Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis

BMC Infectious Diseases, 2021
Background Favipiravir possesses high utility for treating patients with COVID-19. However, research examining the efficacy and safety of favipiravir for patients with COVID-19 is limited.
Toshie Manabe, Dan Kambayashi, Hiroyasu Akatsu, Koichiro Kudo   +3 more
doaj   +1 more source

Unveiling the Potential of B₃O₃ Nanoflake as Effective Transporter for the Antiviral Drug Favipiravir: Density Functional Theory Analysis

Molecules, 2023
In this study, for the first time, boron oxide nanoflake is analyzed as drug carrier for favipiravir using computational studies. The thermodynamic stability of the boron oxide and favipiravir justifies the strong interaction between both species.
Muhammad Nauman Zahid, Naveen Kosar, Hasnain Sajid, Khalid Elfaki Ibrahim, Mansour K. Gatasheh, Tariq Mahmood   +5 more
doaj   +1 more source

Evaluation of Nephrotoxic Properties of Favipiravir Using the RPTEC cell model

Безопасность и риск фармакотерапии, 2023
Scientific relevance. Favipiravir is an antiviral RNA polymerase inhibitor used to treat COVID-19. An adverse drug reaction associated with the use of favipiravir is renal disorder.Aim.
V. A. Evteev, I. S. Semenova, N. D. Bunyatyan, A. B. Prokofiev   +3 more
doaj   +1 more source

When antivirals backfire: An evaluation of favipiravir’s clinical outcomes in critically ill patients with COVID-19: A multicenter cohort study

Journal of Infection and Public Health, 2023
Background: Favipiravir is an oral antiviral, that might treat COVID-19 by enhancing viral eradication, particularly in patients with mild-to-moderate disease.
Khalid Al Sulaiman, Ohoud Aljuhani, Ghazwa B. Korayem, Ali F. Altebainawi, Mashael AlFaifi, Majed Nahari, Alaa Almagthali, Abrar K. Thabit, Raghad Alhajaji, Reham Alharbi, Khawla Kahtani, Abeer A. Alenazi, Aisha Alharbi, Munirah M. Alghwainm, Sara M. Alotaibi, Yazeed S. Alghamdi, Samar Alotaibi, Shaden H. Alonazi, Jumanah M. Almutairi, Ramesh Vishwakarma   +19 more
doaj   +1 more source

Multicenter, single-blind, randomized controlled study of the efficacy and safety of favipiravir and nafamostat mesilate in patients with COVID-19 pneumonia

International Journal of Infectious Diseases, 2023
Objectives: To evaluate the efficacy and safety of nafamostat combined with favipiravir for the treatment of COVID-19. Methods: We conducted a multicenter, randomized, single-blind, placebo-controlled, parallel assignment study in hospitalized patients ...
Mahoko Ikeda, Shu Okugawa, Kosuke Kashiwabara, Takashi Moritoyo, Yoshiaki Kanno, Daisuke Jubishi, Hideki Hashimoto, Koh Okamoto, Kenji Tsushima, Yasuki Uchida, Takahiro Mitsumura, Hidetoshi Igari, Takeya Tsutsumi, Hideki Araoka, Kazuhiro Yatera, Yoshihiro Yamamoto, Yuki Nakamura, Amato Otani, Marie Yamashita, Yuji Wakimoto, Takayuki Shinohara, Maho Adachi-Katayama, Tatsunori Oyabu, Aoi Kanematsu, Sohei Harada, Yuichiro Takeshita, Yasutaka Nakano, Yasunari Miyazaki, Seiichiro Sakao, Makoto Saito, Sho Ogura, Kei Yamasaki, Hitoshi Kawasuji, Osamu Hataji, Jun-Ichiro Inoue, Yasuyuki Seto, Kyoji Moriya   +36 more
doaj   +1 more source

Favipiravir Effectiveness and Safety in Hospitalized Moderate-Severe COVID-19 Patients: Observational Prospective Multicenter Investigation in Saudi Arabia

Frontiers in Medicine, 2022
ObjectivesThere are limited data on the efficacy and safety of favipiravir antiviral in coronavirus disease 2019 (COVID-19), particularly in the more progressed disease phase.
Saleh Al-Muhsen, Nouf S. Al-Numair, Narjes Saheb Sharif-Askari, Roaa Basamh, Banan Alyounes, Amjad Jabaan, Fatemeh Saheb Sharif-Askari, Mohammed F. Alosaimi, Fahad Alsohime, Rabih Halwani, Rabih Halwani, Rabih Halwani, Haya Al-Saud, Haya Al-Saud   +13 more
doaj   +1 more source

Favipiravir for treating COVID-19

Cochrane Database of Systematic Reviews, 2022
The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to challenge the health workforce and societies worldwide. Favipiravir was suggested by some experts to be effective and safe to use in COVID-19.
Korula, Pritish, Alexander, Hanna, John, Jisha Sara, Kirubakaran, Richard, Singh, Bhagteshwar, Tharyan, Prathap, Rupali, Priscilla   +6 more
openaire   +2 more sources